Health and biomedical research funding
4 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- NARODOWE CENTRUM BADAN I ROZWOJU
Poland's national R&D funding agency, co-funding ERA-NET programmes across health, materials, energy, and environment while building Polish centres of excellence.
“Sustained investment in health ERA-NETs: E-Rare-3, TRANSCAN-2, JPco-fuND, ERA-CVD, NEURON Cofund, EuroNanoMed III, ERA PerMed, and CECM centre of excellence.”
PrimaryPL46 projects - FONDS DE LA RECHERCHE SCIENTIFIQUE- FNRS
Belgian national research funding agency (French community) co-financing transnational ERA-NET calls across health, environment, food, and frontier technologies.
“Funds transnational calls in rare diseases (E-Rare-3), neurodegenerative diseases (JPco-fuND), cancer (TRANSCAN-2), cardiovascular disease (ERA-CVD), antimicrobial resistance (JPI-EC-AMR), and personalised medicine (ERA PerMed).”
PrimaryBE46 projects - NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL
Hungary's national R&D funding agency, co-funding transnational ERA-NET programmes across health, quantum technologies, materials, and food systems.
“Co-funding in rare diseases (E-Rare-3, EJP RD), neurodegenerative diseases (JPCOFUND2), antimicrobial resistance (JPIAMR-ACTION), cancer (TRANSCAN-3), and personalised medicine (ERA PerMed).”
HU29 projects - FONDS NATIONAL DE LA RECHERCHE
Luxembourg's national research fund, co-financing transnational ERA-NET calls across health, materials, quantum, and humanities.
“Sustained engagement across ERACoSysMed, JPco-fuND, JPCOFUND2, ERA PerMed, and EJP RD covering systems medicine, neurodegeneration, personalised medicine, and rare diseases.”
PrimaryLU17 projects